share_log

Assenagon Asset Management S.A. Acquires 162,531 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Assenagon Asset Management S.A. Acquires 162,531 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

欣欣資產管理股份有限公司收購彪馬生物科技股份有限公司 162,531 股
Defense World ·  2022/10/23 18:01

Assenagon Asset Management S.A. boosted its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) by 651.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 187,490 shares of the biopharmaceutical company's stock after buying an additional 162,531 shares during the period. Assenagon Asset Management S.A. owned approximately 0.42% of Puma Biotechnology worth $534,000 as of its most recent SEC filing.

根據納斯達克最近提交給美國證券交易委員會的Form 13F文件,Assenagon Asset Management S.A.在第二季度增持了彪馬生物科技公司的股票,增幅為651.2%。該公司持有這家生物製藥公司187,490股股票,在此期間又購買了162,531股。截至最近提交給美國證券交易委員會的文件,Assenagon Asset Management S.A.擁有彪馬生物科技約0.42%的股份,價值534,000美元。

Other large investors also recently added to or reduced their stakes in the company. Running Point Capital Advisors LLC bought a new stake in Puma Biotechnology during the first quarter valued at $29,000. Mackenzie Financial Corp purchased a new stake in Puma Biotechnology during the first quarter valued at about $35,000. Mirabella Financial Services LLP purchased a new stake in Puma Biotechnology during the first quarter valued at about $73,000. UBS Group AG raised its position in Puma Biotechnology by 48.8% during the first quarter. UBS Group AG now owns 25,985 shares of the biopharmaceutical company's stock valued at $75,000 after purchasing an additional 8,523 shares in the last quarter. Finally, Pitcairn Co. purchased a new stake in Puma Biotechnology during the first quarter valued at about $79,000. Institutional investors own 62.26% of the company's stock.

其他大型投資者最近也增持或減持了該公司的股份。Running Point Capital Advisors LLC在第一季度以2.9萬美元的價格購買了彪馬生物科技公司的新股份。麥肯齊金融公司(Mackenzie Financial Corp)在第一季度購買了彪馬生物科技公司的新股份,價值約3.5萬美元。Mirabella Financial Services LLP在第一季度購買了彪馬生物技術公司的新股份,價值約7.3萬美元。瑞銀集團(UBS Group AG)在第一季度將其在彪馬生物科技公司的持倉提高了48.8%。瑞銀集團(UBS Group AG)現在持有這家生物製藥公司25,985股股票,價值75,000美元,上個季度又購買了8,523股。最後,皮特凱恩公司在第一季度購買了彪馬生物科技公司的新股份,價值約7.9萬美元。機構投資者持有該公司62.26%的股票。

Get
到達
Puma Biotechnology
彪馬生物技術
alerts:
警報:

Insider Transactions at Puma Biotechnology

彪馬生物技術公司的內幕交易

In other news, Director Michael Patrick Miller sold 25,000 shares of Puma Biotechnology stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $3.55, for a total value of $88,750.00. Following the transaction, the director now owns 54,858 shares in the company, valued at $194,745.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 28,697 shares of company stock worth $98,411. Company insiders own 21.20% of the company's stock.

在其他新聞方面,董事邁克爾·帕特里克·米勒在一筆日期為8月9日(星期二)的交易中出售了25,000股彪馬生物科技公司的股票。這隻股票的平均售價為3.55美元,總價值為88,750.00美元。交易完成後,董事現在擁有該公司54,858股股份,價值194,745.90美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過這個環節。在上個季度,內部人士出售了28,697股公司股票,價值98,411美元。公司內部人士持有該公司21.20%的股份。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

A number of research firms have weighed in on PBYI. HC Wainwright lowered their price target on Puma Biotechnology from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, August 5th. StockNews.com began coverage on Puma Biotechnology in a research report on Wednesday, October 12th. They set a "buy" rating on the stock.
一些研究公司已經加入了PBYI的行列。8月5日,在一份研究報告中,HC Wainwright將彪馬生物科技公司的目標價從12.00美元下調至8.00美元,並對該股設定了“買入”評級。StockNews.com在10月12日星期三的一份研究報告中開始對彪馬生物技術進行報道。他們對該股設定了“買入”評級。

Puma Biotechnology Stock Up 2.3 %

彪馬生物科技股上漲2.3%

PBYI opened at $2.20 on Friday. The company has a market cap of $100.23 million, a P/E ratio of -2.56 and a beta of 0.65. The business's 50-day moving average price is $2.60 and its 200-day moving average price is $2.66. The company has a current ratio of 2.01, a quick ratio of 1.89 and a debt-to-equity ratio of 4.95. Puma Biotechnology, Inc. has a 12 month low of $1.60 and a 12 month high of $6.76.

上週五,PBYI開盤價為2.20美元。該公司市值為1.023億美元,市盈率為-2.56,貝塔係數為0.65。該業務的50日移動均線價格為2.60美元,200日移動均線價格為2.66美元。該公司的流動比率為2.01,速動比率為1.89,債務權益比率為4.95。彪馬生物科技公司的股價為1.60美元的12個月低點和6.76美元的12個月高位。

Puma Biotechnology (NASDAQ:PBYI – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.02 by $0.19. The firm had revenue of $59.50 million for the quarter, compared to the consensus estimate of $53.20 million. Puma Biotechnology had a negative return on equity of 1,021.09% and a negative net margin of 16.68%. On average, equities analysts expect that Puma Biotechnology, Inc. will post -0.06 EPS for the current year.

彪馬生物科技(納斯達克代碼:PBYI-GET Rating)最近一次發佈季度收益數據是在8月4日星期四。這家生物製藥公司公佈本季度每股收益為0.21美元,比普遍預期的0.02美元高出0.19美元。該公司本季度營收為5950萬美元,而市場普遍預期為5320萬美元。彪馬生物技術公司的淨資產回報率為負1,021.09%,淨利潤率為負16.68%。股票分析師平均預計彪馬生物技術公司本年度每股收益將為0.06歐元。

Puma Biotechnology Company Profile

彪馬生物技術公司簡介

(Get Rating)

(獲取評級)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

彪馬生物技術公司是一家生物製藥公司,專注於產品的開發和商業化,以加強美國和國際上的癌症護理。該公司的候選藥物包括用於HER2過度表達/放大的早期乳腺癌患者的PB272 neratinib(口服);用於將neratinib與卡培他濱結合用於治療晚期或轉移性HER2陽性乳腺癌的成年患者的PB272(neratinib,口服);用於HER2突變陽性實體腫瘤的PB272(neratinib,口服)。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Puma Biotechnology (PBYI)
  • Should Investors Raise a Glass to Boston Beer Company?
  • MarketBeat: Week in Review 10/17-10/21
  • American Express Beats Earnings & Revenue Views, Raises Guidance
  • The Institutions Spin Whirlpool Into Bargain Basement Territory
  • Snap Stock Falls As User Growth Slows To Single-Digits
  • 免費獲取StockNews.com關於彪馬生物技術的研究報告(PBYI)
  • 投資者應該向波士頓啤酒公司舉杯嗎?
  • MarketBeat:回顧一週10/17-10/21
  • 美國運通業績超過盈利和收入預期,提高業績指引
  • 機構將惠而浦打入廉價地下室領域
  • Snap股價下跌,用户增長放緩至個位數

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating).

想看看其他對衝基金持有PBYI嗎?訪問HoldingsChannel.com獲取彪馬生物技術公司(納斯達克代碼:PBYI-GET Rating)的最新13F備案文件和內幕交易信息。

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

獲得彪馬生物技術日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對彪馬生物技術和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論